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Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by
progressive loss of upper and lower motor neurons. Although the etiology remains
unclear, disturbances in calcium homoeostasis and protein folding are essential features
of neurodegeneration in this disorder. Here, we review recent research ﬁndings on the
interaction between endoplasmic reticulum (ER) andmitochondria, and its effect on calcium
signaling and oxidative stress.We further provide insights into studies, providing evidence
that structures of the ER mitochondria calcium cycle serve as a promising targets for
therapeutic approaches for treatment of ALS.
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INTRODUCTION
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative
disorder characterized by progressive degeneration of the upper
(spasticity, dysphagia, dysarthria) and lower motor neurons (atro-
phy, fasciculations). Approximately 90% of ALS patients have
sporadic ALS (sALS) which is the most prevalent form and about
10% have the inherited or familial form of ALS (fALS). The lat-
ter form is believed to be due to several genes including SOD1,
Abbreviations: ALS, amyotrophic lateral sclerosis; AMPA, α-amino-5-methyl-
3-hydroxisoxazolone-4-propionate; ANT, adenine nucleotide translocator; AP-1,
activator protein 1; ARE, antioxidant response element; ATF6, basic leucine-zipper
transcription factor 6; Bax/Bak, Bcl-2-associated X protein; Bcl-2, B-cell lymphoma
2 protein; BIK, Bcl-2 interacting killer protein; C9ORF72, chromosome 9 open
reading frame 72; CHOP, transcription factor C/EBP homologous protein; eIF2α,
eukaryotic initiation factor-2; ER, endoplasmic reticulum; ERMCC, endoplasmic
reticulum mitochondria calcium cycle; fALS, familial amyotrophic lateral sclerosis;
FUS/TSL, fused in sarcoma/translated in liposarcoma; HIF-1α, hypoxia-induced
factor; Hsf1, heat shock transcription factor 1; InsP3, inositol 1,4,5-trisphosphate;
IP3R, inositol 1,4,5-triphosphate receptor-gated channel; IRE1, inositol-requiring
enzyme 1; mNCE,mitochondrial sodium calcium exchanger; mPTP,mitochondrial
permeability transition pore; mUP, mitochondrial uniporter; NF-κB, nuclear factor
kappa-light-chain-enhancer of activated B cells; NO, nitric oxide; Nrf2, erythroid
2-related-factor 2; OPTN, optineurin; PDI, protein disulﬁde isomerase; PERK,
the double-stranded RNA-activated protein kinase (PKR)-like ER kinase; PLCδ1,
phospolipase C delta 1; ROS, reactive oxygen species; RyR, ryanodine receptors;
sALS, sporadic amyotrophic lateral sclerosis; SERCA, sarco/endoplasmic reticulum
Ca2+ ATPase; SOD1, Cu/Zn superoxide dismutase type 1; SR, sarcoplasmic reticu-
lum; TARDBP, TAR DNA binding protein; TCTP, translationally controlled tumor
protein; TDP-43, transactive response DNA binding protein 43 kDa; UBQLN2,
ubiquilin-2; UCH-L1, ubiquitin carboxy-terminal hydrolase L1; UPR,unfoldedpro-
tein response; VAPB, vesicle-associated membrane protein (VAMP)-associated pro-
tein B; VCP, valosin-containing protein; VDAC, voltage-dependent anion channel.
TARDBP, FUS, OPTN, and VCP. In addition, a hexanucleotide
(GGGGCC) repeat expansion in the ﬁrst intron of the C9ORF72
gene (DeJesus-Hernandez et al., 2011; Renton et al., 2011) has
lately been demonstrated as being associated with ALS. How-
ever, the etiology of the disease is still unclear, although recent
studies indicate that calcium (Ca2+) disturbances, ER stress, and
mitochondrial dysfunction are involved in the pathogenesis of
ALS (Grosskreutz et al., 2010; Lautenschlaeger et al., 2012). Other
mechanisms possibly involved in ALS-related pathophysiology
comprise: oxidative stress, protein aggregation, dysregulated endo-
somal trafﬁcking, impaired axonal transport, neuroinﬂammation,
and dysregulated transcription and RNA processing (Ferraiuolo
et al., 2011). Several properties of motor neurons make them
more vulnerable than other neuronal groups. Motor neurons
express high levels of Ca2+–permeable α-amino-5-methyl-3-
hydroxisoxazolone-4-propionate (AMPA) receptors that lack the
GluR2 subunit which makes them more vulnerable to excitotoxic-
ity and dysregulation of intracellular Ca2+ homeostasis (Williams
et al., 1997). Also, low levels of Ca2+ -buffering proteins con-
tributes greatly to this vulnerability (Ince et al., 1993). Because
of high metabolic demands, motor neurons are largely depen-
dent on optimal mitochondrial function, a robust cytoskeleton
and an axonal transport mechanism. Despite all the above facts,
there remain numerous unanswered questions in ALS related
to selectivity and speciﬁcity of the cellular targets of motor
neuron degeneration and cell-speciﬁc aspects of mitochondrial
Ca2+ signaling. This review focuses on crosstalk between ER,
mitochondria, oxidative stress and calcium.
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ALS GENES AND ENCODED PROTEINS – ROLE IN PATHOPHYISOLOGY
Cu/Zn superoxide dismutase 1 (SOD 1)
About 20% of fALS patients carry a mutation in the SOD1 gene.
Indeed, more than 170 different SOD1 mutations have been
described in ALS families (http://alsod.iop.kcl.ac.uk/). Generally,
SOD1 mutations have not been linked to decreased SOD activ-
ity (Kostrominova, 2010; Fischer et al., 2011), instead mutant
SOD1 likely acts through a combination of several mechanisms,
including protein misfolding, mitochondrial dysfunction, oxida-
tive damage, cytoskeletal abnormalities, and defective axonal
transport, excitotoxicity, in addition to inadequate growth factor
signaling and inﬂammation (Cozzolino et al., 2008).
Fused in sarcoma (FUS) and TAR DNA-binding protein (TDP-43)
Mutations in the gene encoding fused in sarcoma/translocated
in liporsarcoma (FUS/TLS or FUS) are linked to 4% of fALS
cases. Mutations in TARDBP (which encodes TDP-43) account
for 4% of fALS and a smaller percentage of sALS. The toxic-
ity of TDP-43 and FUS/TSL proteins is linked to their altered
intracellular localization. Both TDP-43 and FUS/TLS are mainly
localized in cell nuclei where they control gene transcription and
pre-mRNA (Buratti et al., 2001; Winton et al., 2008; Kwiatkowski
et al., 2009). In the presence of mutations or stress, these pro-
teins accumulate in the cytosol (Liu-Yesucevitz et al., 2010; Dewey
et al., 2012; Daigle et al., 2013; Walker et al., 2013; Watanabe
et al., 2013). FUS triggers ER stress and causes fragmentation
of the Golgi apparatus in patients with fALS (Farg et al., 2013).
In NSC34 transfected cells, wild type human TDP-43 caused ER
stress (Suzuki et al., 2011). In the same cell line, mutant TDP-43
induced mitochondrial dysfunction and probably caused oxida-
tive stress (Duan et al., 2010). Experiments with TDP-43 mutation
in zebraﬁsh resulted in impairment of neuromuscular junctions
(Armstrong and Drapeau, 2013).
Chromosome 9 open reading frame 72 (C9ORF72)
Large expansions of a non-coding GGGGCC-repeat in the ﬁrst
intron of the C9ORF72 gene are accountable for 40% of fALS.
C9ORF72 hexanucleotide repeats form highly stable RNA G-
quadruplexes, which probably inﬂuence RNA transcription, splic-
ing, translation and transport (Fratta et al., 2012). C9ORF72
pathology is characterized by intracellular inclusions, however
the major proteins forming these inclusions have not yet been
elucidated (Mori et al., 2013).
Other genes
Mutations in the valosin–containingprotein (VCP) are responsible
for 1–2% of fALS cases. In mice, overexpression of mutant VCP
produces ubiquitin- and TDP-43-positive inclusions, suggesting
that TDP-43 plays a role inVCP-induced disease (Rodriguez-Ortiz
et al., 2013). Mutant VCP also impact mitochondria, such as via a
decrease in ATP production related to mitochondrial uncoupling
(Bartolome et al., 2013).
Another mutated gene found in patients with ALS comprises
OPTN that encodes the protein optineurin which regulates mem-
brane trafﬁcking, protein secretion, cell division and host defense
against pathogens (Kachaner et al., 2012). Wild-type optineurin
suppresses nuclear factor-kappa B (NF-κB) activity, but the
ALS-causingmutant optineurin is unable to suppressNF-κB activ-
ity. Therefore, there is an indication that inappropriate NF-κB
activation is the pathogenic mechanism underlying optineurin
mutation-related ALS (Akizuki et al., 2013). In two patients carry-
ing mutation in OPTN, was shown that loss of function rather
than proteinopathy itself resulted in the formation of TDP-43
inclusions in neuronal and glial cytoplasm, and Golgi apparatus
fragmentation (Kamada et al., 2014).
Vesicle-associated membrane protein (VAMP)-associated pro-
tein B (VAPB) is usually ER-resident and is integral to its structure,
protein transport, lipid metabolism, and the UPR. VAPB toxicity
is probably mediated by impaired Ca2+ homeostasis and ER stress
(Langou et al., 2010; De Vos et al., 2012; Morotz et al., 2012).
THE ERMCC AND CALCIUM DISTURBANCES IN ALS
The ER and mitochondria form a highly dynamic interconnected
network that is involved in the generation of Ca2+ signals. Ca2+
release from ER is controlled by ryanodine receptors (RyRs, Ca2+-
gated Ca2+ channels) (Meissner, 2002; Lanner et al., 2010), the
inositol 1,4,5-triphosphate receptor-gated channels (IP3Rs), and
the translocon (Taylor and Tovey, 2010). Restocking of the ER
with Ca2+ is executed by the sarco/endoplasmic reticulum Ca2+
ATPase (SERCA; Wuytack et al., 2002; Verkhratsky, 2005; Lip-
skaia et al., 2009). Ultimately, the plasma membrane Na+/Ca2+
exchanger and Ca2+ ATPase remove Ca2+ from the cell (Rhodes
and Sanderson, 2009; Figure 1).
Mitochondria take up Ca2+ via a Ca2+-sensitive electro-
genic carrier, the mitochondrial uniporter (mUP) which is gated
by cytosolic Ca2+ in a biphasic-dependent manner (Gunter
and Sheu, 2009). Ca2+ uptake into mitochondria is facilitated
by Ca2+/calmodulin. However, sustained cytosolic Ca2+ lev-
els inactivate the uniporter, preventing further Ca2+ uptake
(Moreau et al., 2006). Accumulated Ca2+ in the mitochondria can
slowly be ejected back into the cytosol through Na+/Ca2+ and
2H+/Ca2+ exchangers (Pivovarova and Andrews, 2010; Figure 1).
Once intramitochondrial Ca2+ rises above a certain threshold,
the voltage- and Ca2+-dependent high-conductance channel in
the inner membrane, known as the mitochondrial permeabil-
ity transition pore (mPTP), opens, leading to cell death either
by apoptosis or necrosis (Leung and Halestrap, 2008; Mar-
tin, 2010b). Mitochondria contain similar low Ca2+ levels as
resting cells, but accumulate a considerable amount during stim-
ulated Ca2+ entry, which affects numerous cellular processes
such as cellular energy metabolism, synaptic transmission and
excitability, intracellular signaling, generation of ROS, and acti-
vation of apoptosis (Chinopoulos and Adam-Vizi, 2010; Starkov,
2010).
Several studies have previously investigated abnormalities of
Ca2+ homeostasis, ER and mitochondria as well as excitotoxicity
in motor neurons in ALS (Grosskreutz et al., 2010; Lautenschlager
et al., 2013). Based on the models described by Berridge (2002),
a persistent shift of Ca2+ from the ER to mitochondria (i.e.,
through Ca2+induced Ca2+ release via RyR and mitochondrial
uptake through mUP) was postulated. This could be triggered
by the physiological activity of AMPA receptors together with
a pathologically increased Ca2+-permeability (Grosskreutz et al.,
2010). This in turn, leads to a depletion of Ca2+ levels in the ER,
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FIGURE 1 |The endoplasmic reticulum mitochondria Ca2+cycle
(ERMCC). Ca2+can enter cytosol through: the AMPA receptor, the ryanodine
receptor (RyR) at the ER membranes, the opening of the inositol 1,4,5
trisphosphate receptor (IP3R), the translocon at the ER membrane, and/or the
plasmalemmal voltage gated Ca2+channels (VGCC).Triggered by physiological
activity of AMPA receptors with pathologically increased Ca2+-permeability in
ALS, a chronic shift of Ca2+ from the ER to the mitochondria (i.e., through
Ca2+-induced Ca2+release through RyR and mitochondrial uptake through
the uniporter mUP) causes depletion of ER Ca2+ levels with protein
misfolding (UPR) and chronic mitochondrial Ca2+overload. Cytosolic
Ca2+clearance is facilitated by the plasma membrane Ca2+ATPase, the
plasmalemmal Na+/Ca2+exchanger (NCE), the sarco/endoplasmicreticulum
Ca2+ATPase (SERCA), and the Golgi apparatus. Astrocytes control the level
of persisting glutamate at the glutamatergic synapse through glutamate
transporters (EAAT), but also exert life-supporting functions in motor neurons
(i.e., BDNF, IGF, VEGF). (NMDAR = NMDA receptors, VGCC = voltage gated
Ca2+channels, Na/K = Na+/K+pump, pNCE = plasmalemmal Na+/Ca2+
exchanger, PMCA = plasmalemmal Ca2+ATPase, mNCE = mitochondrial
Na+/Ca2+ exchanger, SERCA = sarco-endoplasmic Ca2+ATPase). Modiﬁed
picture taken from (Prell et al., 2013).
resulting in protein folding dysfunction and chronic mitochon-
drial Ca2+ overload. Both protein misfolding and Ca2+ overload
can then induce apoptosis through Bcl-2 dependent mechanisms
(Grosskreutz et al., 2010). Since Ca2+ appears to be shuttled back
and forth between the ER and the mitochondrial compartment,
the process has been termed the ER–mitochondria Ca2+ cycle
(ERMCC, Figure 1; Grosskreutz et al., 2010).
IMPACT OF ER STRESS ON MITOCHONDRIA
Recent studies indicate that ER stress is involved in the pathogen-
esis of familial and sporadic ALS (Ilieva et al., 2007; Atkin et al.,
2008; Walker, 2010; Lautenschlaeger et al., 2012; Prell et al., 2012).
ER stress occurs when ER Ca2+ content is depleted (Verkhratsky,
2005) and misfolded proteins accumulate in the ER. To cope
with ER stress, cells activate the unfolded protein response (UPR;
Figure 2). The UPR mediates the (1) upregulation of genes
encoding ER-resident chaperones, (2) down-regulation of general
protein synthesis in order to reduce the ER protein load, and, (3)
degradation of misfolded proteins by the proteasome (Kozutsumi
et al., 1988; Yoshida et al., 2001; Dudek et al., 2009; Figure 2). On
a cellular level, ER stress is transduced by three proximal sensors
of the UPR: the double-stranded RNA-activated protein kinase
(PKR)-like ER kinase (PERK), the basic leucine-zipper transcrip-
tion factor 6 (ATF6) and the inositol requiring enzyme 1 (IRE1)
(Prell et al., 2013; Figure 2). When protein misfolding can no
longer be compensated for, the prolonged UPR triggers apoptosis
by the caspase pathways (Nakagawa et al., 2000; Figure 2).
ER stress can affect mitochondria because both organelles are
functionally and morphologically connected by several pathways
(Vannuvel et al., 2013). In particular, the contact between ER and
mitochondria is essential for coordination of the Ca2+ transfer
(Rowland andVoeltz, 2012). The proteins B-cell lymphoma 2 (Bcl-
2), Bcl-2-associated X protein (Bax/Bak) and the Bcl-2-interacting
killer (BIK) can enhance Ca2+ transfer from ER to mitochon-
dria and the ensuing Ca2+ accumulation activates apoptosis via
cytochrome C (Germain et al., 2002; Nutt et al., 2002; Fannjiang
et al., 2004; Kong et al., 2005). ThePERK/ATF4pathway can induce
Lon protease that controls the assembly and/or the degradation of
cytochrome C (Margineantu et al., 2002; Venkatesh et al., 2012).
Bid, which is a pro-apoptotic BH3-only protein can be cleaved
upon ER stress, which subsequently activates caspase-2 or caspase-
8 leading to apoptosis (Upton et al., 2008; Uchibayashi et al., 2011).
Recruitment of the dynamin-related protein 1 mediates the ﬁssion
of the outer mitochondrial membrane (Breckenridge et al., 2003).
Frontiers in Cellular Neuroscience www.frontiersin.org May 2014 | Volume 8 | Article 147 | 3
Tadic et al. ERMCC as target in ALS
FIGURE 2 | (A) Motor neuron in a physiological state and under ER stress
conditions. In motor neurons, most proteins in the ER are physiologically
properly folded. The ER chaperones Grp78 (78) and protein disulﬁde
isomerase (PDI) are moderately expressed and assist protein folding. The
unfolded protein response (UPR) sensor proteins (IRE1, PERK, ATF6) are
bound to Grp78 and are therefore in an inactive state. (B) Upon ER stress,
Grp78 dissociates from IRE1, PERK and ATF6 resulting in the activation and
up-regulation of these three UPR sensor proteins. IRE1 splices XBP-1 mRNA
(sXBP-1) which up-regulates the expression of UPR relevant genes. ATF6 is
transported to Golgi apparatus, where it is cleaved. The cytosolic domain of
ATF6 translocates to the nucleus to activate gene expression. PERK
phosphorylates eIF2α, thereby down-regulating the total protein synthesis to
prevent an overload of the ER. Once the expression of ER chaperones Grp78
and PDI is induced, they bind to the misfolded proteins and try to assist their
folding. If restoring of ER homeostasis fails, cell death proteins transcription
factor C/EBP homologous protein (CHOP) and caspase 12 (casp 12) are
induced and the balance of Bcl-2 family members is disturbed, anti-apoptotic
Bcl-2 family members are down-regulated, while pro-apoptotic Bcl-2 family
members are up-regulated. Picture modiﬁed from (Lautenschlaeger et al.,
2012).
THERAPEUTIC STRATEGIES FOCUSED ON ER STRESS
Several therapeutic strategies aim to target the ER (Table 1;
Figure 4). For instance, Salubrinal is a substance that reduces ER
stress by activating the UPR. UPR activation is mediated via phos-
phorylation of elF2α and activation of PERK (Boyce et al., 2005).
Salubrinal prevented neuronal cell death triggered by several ER
stress inducers (Smith et al., 2005; Reijonen et al., 2008). More-
over, Salubrinal, Guanabenz and Phenazine have all been shown to
reduce ER stress in worms and zebraﬁsh expressing mutated TDP-
43 (Vaccaro et al., 2013). In SOD1G93Amice, Salubrinal decreased
muscle strength loss and extended survival (Saxena et al., 2009).
Another approach to target the ER is to encourage the nat-
ural cellular protein-folding machinery via activation of the
heat shock transcription factor 1 (Hsf1). Hsf1 is the mas-
ter activator of chaperone protein gene expression (Neef et al.,
2011). Overexpression of human molecular chaperone hHSJ1a
in vivo mediated late-stage neuroprotection in the SOD1G93A
mouse model, probably through a combination of chaper-
one, co-chaperone and pro-ubiquitylation activity on SOD1
(Novoselov et al., 2013). Arimoclomol, a hydroxylamine derivate
and a co-inducer of the heat shock response delayed muscle
denervation in the SOD1G93A mouse followed by a rise in
expression of the heat shock protein 70 (Kalmar et al., 2012).
The therapeutic potential of this drug is under investigation
in a phase II/III clinical trial for ALS patients with SOD1
mutations (http://www.clinicaltrials.gov/ct2/show/NCT00706147?
term=arimoclomol&rank=1). Other available pharmaceuticals
that up-regulate heat shock response and that may be used to
treat ALS include Celastrol and 17-AAG (Kalmar et al., 2014).
Accumulation of misfolded proteins may also be targeted by
small molecule regulators of autophagy such as antipsychotics
(ﬂuspirilene, triﬂuoperazine, pimozide) and calcium-channel
Frontiers in Cellular Neuroscience www.frontiersin.org May 2014 | Volume 8 | Article 147 | 4



























































































































































































































































































































































































































































































































































































































































































































































































































































































Frontiers in Cellular Neuroscience www.frontiersin.org May 2014 | Volume 8 | Article 147 | 5
Tadic et al. ERMCC as target in ALS
modulators (nicardipine, niguldipine, amiodarone; Sarkar et al.,
2007; Zhang et al., 2007).
The Sigma-1 receptors have also gained attention in the
recent past. The receptors are a chaperone proteins residing at
the mitochondrion-associated ER membrane, where they affect
mitochondrial Ca2+ inﬂux by stabilizing IP3R and acting as inter-
organelle signaling modulators of Ca2+ homeostatasis, ER stress
and apoptosis. The Sigma-1 receptor agonist PRE-084 prevented
neurons loss in SOD1G93A transgenic mice, probably by the
activation of protein kinase C and reducing microglia activation
(Mancuso et al., 2012). Neuroprotective effects of PRE-084 have
also been demonstrated in the wobbler mouse model not linked to
SOD1 mutation that is characterized by progressive neural atro-
phy shortly after birth (Peviani et al., 2014). Another agonist of
Sigma-1 receptor SA4503 prevented SOD1G93A–induced neuro-
toxicity in NSC34 cells and extended survival of SOD1G93A mice
(Ono et al., 2014). Pharmacological manipulation of the Sigma-
1 receptor may increase availability of growth factors, as well as
the modulation of astrocytosis and of macrophage/microglia as
part of the mechanism involved in Sigma 1 receptor-mediated
neuroprotection (Peviani et al., 2014).
Treatment with Geldanamycin, an inducer of heat shock
response, successfully blocked protein aggregation but not Ca2+
dysregulation or loss of mitochondrial membrane potential
(Ψ) in murine motor neurons expressing human SOD1G93A
(Tradewell et al., 2011). This implies chaperone-based thera-
pies would possibly require co-therapy targeting other important
mechanisms of toxicity.
CROSS-TALK BETWEEN CALCIUM, MITOCHONDRIA, AND
REACTIVE OXYGEN SPECIES SIGNALING
MITOCHONDRIAL DYSFUNCTION
Mitochondria are central for energy metabolism and have been
well studied in relation to ALS pathogenesis (von Lewinski and
Keller, 2005; Cozzolino and Carri, 2012; Jaiswal, 2013). The lev-
els of mutated mitochondrial DNA (mtDNA) were higher in ALS
patients but the amount of mtDNA was reduced compared to
controls. This reduction correlated well with a decrease of a mito-
chondrial marker, citrate synthase activity and with the activities
of respiratory chain complexes I + III, II + III, and IV, sug-
gesting a loss of mitochondria in ALS spinal cords (Wiedemann
et al., 2002). Activity of cytochrome C oxidase in mitochondria
is reduced in the spinal cord of sALS patients (Borthwick et al.,
1999) and ALS spinal neurons show varied and reduced mtDNA
gene copy numbers and increased mtDNA gene deletions (Keeney
and Bennett, 2010). Oxidative stress, protein nitration and aggre-
gation, and excitotoxicity participate in the process of motor
neuron degeneration caused by mutated SOD1 (Martin et al.,
2007). One of the pathological hallmarks of ALS is aggregation
of ubiquitinated proteins in motor neurons (Stieber et al., 2000;
Figure 3). SOD1, FUS, TDP-43, OPTN, and UBQLN2 have been
identiﬁed as forming aggregates.Whether there is a causal relation-
ship between misfolded proteins and mitochondrial dysfunction
for novel mutations is still largely unknown, but there is con-
siderable body of literature describing SOD1 and more recently
TDP-43. Mutant SOD1 forms insoluble aggregates in mitochon-
dria at the surface of the outermembrane (Figure 3). Further, there
is direct connection between mutated SOD1 and impaired mito-
chondrial function (Liu et al., 2004; Pasinelli et al., 2004; Pickles
et al., 2013). Bcl-2 has been identiﬁed as an interacting partner of
mutated SOD1 because SOD1 induces mitochondrial morpholog-
ical changes and impairs mitochondrial membrane integrity only
in the presence of Bcl-2. This leads to the release of cytochrome C,
ultimately leading to cell death (Pedrini et al., 2010).
Degenerating mitochondrial vacuoles have been reported in
presymptomaticmice expressingmutant SOD1 inprevious studies
(Wong et al., 1995; Kong and Xu, 1998). However, mitochon-
drial disturbances are not restricted to SOD1 mutations. In
patients with ALS, dense conglomerates of mitochondria have
been found in the anterior horn of lumbar and spinal cord and
proximal axons (Hirano et al., 1984; Sasaki and Iwata, 1996). It
has been demonstrated that neuronal Ca2+, mitochondrial vol-
ume and a number of synaptic vesicles are increased in ALS
patients (Siklos et al., 1996). In addition, overexpression of TDP-
43 causes mitochondrial dysfunction and induces mitophagy
(Hong et al., 2012) and oxidative injury in NSC34 cell line (Duan
et al., 2010; Lu et al., 2012). In a yeast model, TDP-43 aggre-
gates around mitochondria and there is an inverse correlation
between respiratory activity and toxicity of the mutant pro-
tein (Braun et al., 2011). Overexpression of wild-type TDP-43
resulted in reduced mitochondrial length and density in neu-
rites of primary motor neurons and conversely, suppression of
TDP-43 resulted in signiﬁcantly increased mitochondrial length
and density in neurites (Wang et al., 2013). Neuronal mitochon-
drial transport and morphological abnormalities occur in vivo in
SOD1 and TDP-43 ALS (Figure 3) mouse models but show dif-
ferences in temporal and spatial manifestation. This implies that
different molecular mechanisms may be involved (Magrane et al.,
2013).
MITOCHONDRIAL CALCIUM DYNAMICS
Ca2+ regulation of mitochondrial metabolism
Ca2+ plays a central role in cell signaling at numerous levels. The
tricarboxylic acid cycle consists of a series of reactions that produce
energy through the breakdown of proteins, fatty acids and carbo-
hydrates. Ca2+ within mitochondria regulates the most important
task of the organelle: ATP production by oxidative phosphoryla-
tion. The physiological increase of mitochondrial Ca2+ stimulates
the adenine nucleotide transporter (Mildaziene et al., 1995) and
synthesis of ATP complex V (Das and Harris, 1990). Moreover,
mitochondrial Ca2+ increase activates three matrix dehydroge-
nases: isocitrate dehydrogenase, α-ketogluterate dehydrogenase
and pyruvate dehydrogenase (McCormack and Denton, 1979,
1993; McCormack et al., 1990). All three dehydrogenases enhance
the reaction rate of many of the steps in the tricarboxylic acid cycle
and therefore increase ﬂux throughout the pathway, raising ATP
production (Jouaville et al., 1999). Furthermore, it has been shown
that motor neurons have an insufﬁcient mitochondrial capacity
to buffer large Ca2+ elevations which is partly due to a reduced
mitochondrial density per volume compared to non-motor neu-
rons (Grosskreutz et al., 2007). Mitochondrial disfunction and
impaired Ca2+ homeostasis largely contribute to selective vulner-
ability of motor neurons (Jaiswal et al., 2009; Jaiswal and Keller,
2009).
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FIGURE 3 | Calcium dysregulation, ER stress and mitochondrial
impairment are major components of excitotoxicity in motor neurons.
Mitochondrial dysfunction causes activation of proteolytic and ROS
generating-generating enzyme systems. Mutant SOD1 forms insoluble
aggregates in mitochondria at the surface of the outer membrane. Motor
neuron might also undergo transcriptional dysregulation and abnormal RNA
processing which together with depleted ER Ca2+ levels and overproduction
of ROS contribute to aberrant protein folding. Aberrant proteins form
aggregates leading to ER stress and ultimately activating apoptotic pathways,
especially when the unfolded protein response is exhausted. Impaired axonal
transport may also contribute to an energy deﬁcit in the distal axon and the
dying back axonopathy that is observed in ALS.
Ca2+ overload and activation of permeability transition pore
One main mediator of mitochondrial function or dysfunction
in neurons is the mPTP, which is a Ca2+ dependent high-
conductance channel in the inner membrane of mitochondria
(Brenner and Moulin, 2012). The mPTP comprises of the
voltage-dependent anion channel (VDAC), the adenine nucleotide
translocator (ANT) and cyclophilin D. Since VDAC and ANT
are not essential for functioning of mPTP regulator (Juhaszova
et al., 2008), the soluble matrix protein cyclophilin D received
special attention (Giorgio et al., 2010). The mPTP opening is
promoted by binding of cyclophilin D to the inner mitochon-
drial membrane (Di Lisa and Bernardi, 2009) and is favored
by Ca2+ overload, ROS, inorganic phosphate and mitochon-
drial depolarization (Crompton, 1999; Brustovetsky et al., 2002;
Bernardi et al., 2006). Binding of cyclophilin D to the inner
mitochondrial membrane can be prevented by Cyclosporine A.
Opening the mPTP causes a release of cytochrome C, which sub-
sequently leads to apoptotic cell death (Liu et al., 1996; Crompton
et al., 1998). High concentrations of cyclophylin D were found
in swollen mitochondria in the SOD1 animal model. Modifying
mPTP through different genetic and pharmacological manipu-
lations has been shown to be protective in animal models of
ALS. Genetic ablation of cyclophilin D delayed disease onset and
extended the lifespan in the ALS mouse model (Martin et al.,
2009). However, in another study, deleting cyclophilin D in
the SOD1 mouse model did not lead to prolongation of sur-
vival, although it improved mitochondrial buffering capacity and
attenuated mitochondrial damage (Parone et al., 2013). Therefore
the role of cyclophylin D as a potential therapeutic is not fully
understood.
Therapeutic strategies focused on mitochondrial Ca2+ dynamics
Because there is growing evidence for mitochondrial dysfunc-
tion in ALS, mitochondria are promising therapeutic targets
(Table 2; Figure 4). However, studies targeting mitochon-
dria have failed so far. The mPTP modulator Olesoxime
(TRO19622) had a neuroprotective effect in motor neuron
cell culture and in ALS rodents (Bordet et al., 2007; Martin,
2010a; Sunyach et al., 2012), but failed in a phase III clinical
trial (http://www.als.net/ALS-Research/Olesoxime/ALS-Topics/).
Further, Dexpramipexole, which reduces mPTP opening and
increases cellular energy supply, did not have signiﬁcant
effects on survival and disease progression in a recent clinical
trial (Cudkowicz et al., 2013).
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Minocycline and creatine, compounds that improvemitochon-
drial function have also failed in human trials (Shefner et al., 2004;
Gordon et al., 2007). Other medications targeting mitochondria
such as coenzyme Q and cylosporin A have been studied, but
all trials in humans were negative (Appel et al., 1988; Kaufmann
et al., 2009). Uridine, a pyrimidine nucleoside, extended survival
in SOD1G93A mice, probably by improving bioenergetic effects,
increasing ATP levels, and enhancing glycolytic energy produc-
tion (Amante et al., 2010). However, it has not been tested in ALS
patients yet.
Melatonin recently gained interest because of its ability to
decrease cytochrome C release and caspase-3 activation. It delayed
disease onset in the SOD1G93A mice model. Besides its mito-
chondria stabilization effects in ALS, melatonin attenuated the
activation of astrocytes and microglia (Zhang et al., 2013).
CGP37157, which is able to cross blood-brain barrier
(Gonzalez-Lafuente et al., 2012), blocks the mNCE. It showed pro-
tective effects against kainate induced excitotoxicity in SOD1G93A
micemotor neurons (Lautenschlager et al., 2013), restored calcium
levels in SOD1G37R N2 cells (Coussee et al., 2011) and pro-
tected rat hippocampal slices upon veratridine-induced sodium
and calcium overload (Gonzalez-Lafuente et al., 2012).
The transport of ADP, ATP and inorganic phosphates across
mitochondrial membranes is regulated by the VDAC at the outer
mitochondrial membrane. VDAC is regulated by Bcl-2 and both
can form toxic complexes with mutated SOD1 (Pasinelli et al.,
2004; Arbel and Shoshan-Barmatz, 2010; Israelson et al., 2010;
Pedrini et al., 2010). Interactions between VDAC1, Bcl-2 and
mutated SOD1 inhibits the conductance of VDAC1, leading to
cell death (Israelson et al., 2010; Pedrini et al., 2010). It was
demonstrated that small SOD1-like therapeutic peptides specif-
ically block the formation in symptomatic SOD1G93A mice by
restoring mitochondrial ADP permeability (Tan et al., 2013).
Human TDP-43 caused mitochondrial morphologic abnor-
mality and decrease of mitochondrial complex I activity, and
mitochondrial transmembrane potential in human TDP-43 stably
tranfected NSC-34 cells. Dimethoxy curcumin was able to ame-
liorate mitochondrial dysfunction in the same experiment, which
makes this drug interesting as a potential therapeutic for TDP-43
linked ALS (Lu et al., 2012).
CALCIUM AND MITOCHONDRIAL ROS
Mitochondria are the main sites of ROS formation as by-products
of ATP production (Coyle and Puttfarcken, 1993; Brand, 2010).
However, mitochondrial Ca2+ overload and abnormal oxida-
tive phosphorylation increase ROS production and oxidative
stress (Carriedo et al., 2000; Mattiazzi et al., 2002; Murphy, 2009;
Figure 3). Many of the stated mitochondrial respiratory abnor-
malities have been linked to reduced activity of mitochondrial
complexes I and IV (Mattiazzi et al., 2002; Rizzardini et al., 2006;
Son et al., 2008; Coussee et al., 2011).
Reactive oxygen species and oxidative stress
Moderate levels of ROS and reactive nitrogen species (RNS) pro-
mote cellular proliferation, regulation and survival. Typical ROS
are free radical species such as superoxide (O•−2 ), hydroxyl radicals
(•OH) and non-radical species like hydrogen peroxide (H2O2).
The respiratory chain complexes I and III are the primary mito-
chondrial sources of O•−2 Oxidative stress has been implicated
as a pathological mechanism of both fALS and sALS (Ferrante
et al., 1997). ROS has been detected in the spinal cord and cere-
brospinal ﬂuid of sALS patients (Tohgi et al., 1999). Increased
H2O2 and oxidative damage to protein and DNA were observed
in mutated SOD1 transgenic mice (Liu et al., 1999). Many ALS
causing genes and genes modiﬁers are known to inﬂuence ROS
production (Carter et al., 2009). SOD1 mutation induces oxida-
tivemodiﬁcations of several proteins inALS: SOD1, translationally
controlled tumor protein (TCTP), ubiquitin carboxyl-terminal
hydrolase-L1 (UCH-L1) and probably alphaB-crystallin. These
oxidative modiﬁcations lead to structural alteration and a decline
of protein activity (Poon et al., 2005). ROS also directly inﬂu-
ences transcriptional factors such as NF-kB, activator protein 1
(AP-1), and HIF-1α which are all involved in the regulation of
gene expression and maintaining cellular homeostasis (Haddad,
2002).
ROS dysregulation of these factors is observed in ALS pathol-
ogy (Iaccarino et al., 2011; Moreau et al., 2011) as the involvement
of protein disulﬁde isomerase (PDI) family members plays an
important role in oxidative folding of human secretory pro-
teins (Rutkevich et al., 2010; Figure 2). PDI’s enzymatic activity
can be inactivated by oxidation and S-nitrosylation of their
active site thiol groups. In motor neurons of patients with
ALS, PDI was widely distributed and aggregated (Atkin et al.,
2008). Therefore it was assumed that PDI is inactivated due to
S-nitrosylation in the affected neurons, which causes protein mis-
folding in ALS (Honjo et al., 2011). Studies of genetics, model
organisms, and patient’s tissue samples support PDI upregula-
tion triggered by ER stress and post-translational inhibition of
PDI due to S-nitrosylation (Atkin et al., 2008; Walker and Atkin,
2011).
Therapeutic strategies focused on reactive oxygen species
Design of novel antioxidant strategies to selectively target oxida-
tive stress and redox imbalance might be an important approach
(Table 3; Figure 4). However, the antioxidant treatment ther-
apy in ALS has not been successful so far (Traynor et al., 2006;
Bedlack et al., 2007; Beghi et al., 2011). SOD1 is tightly con-
nected with the nuclear erythroid 2-related-factor 2 (Nrf2). Nrf2
is a transcriptional factor and main expression regulator of
many antioxidant/detoxiﬁcation genes via its interaction with the
antioxidant response element (ARE). Because it helps neuronal
cells to cope with toxic effect of oxidative stress, pharmacologi-
cal targeting of Nrf2/ARE pathway was proposed as a tool against
neurodegeneration in ALS (Petri et al., 2012; Milani et al., 2013;
Figure 4). S(+9)-Apomorphine, a CNS penetrating activator of
the Nrf2/ARE pathway was able to reduce pathological oxidative
stress and improved survival in ﬁbroblasts of ALS patients, and
also slowed disease progression in SOD1G93mice (Mead et al.,
2013). On the other hand, Guo et al. (2013) reported a rather
modest impact of Nrf2 on the course of disease in SOD1G93A
mice.
Beneﬁcial effects have been reported in NSC-34 cells for mela-
tonin, a hormone which acts against oxidative and nitrosative
stress-induced damage (Weishaupt et al., 2006). In several
Frontiers in Cellular Neuroscience www.frontiersin.org May 2014 | Volume 8 | Article 147 | 9
Tadic et al. ERMCC as target in ALS
FIGURE 4 | Summary of substances targeting ER, mitochondria,
oxidative stress and altered Ca2+ homeostasis. Salubrinal increases the
unfolded protein response (UPR) via phosphorylation of elF2α and activation
of PERK. Arimoclomol induces heat shock response. PRE-084 activates
Sigma-1 receptor. Uridine increases bioenergetic effects, increases ATP and
enhances glycolytic energy production. CGP37157 blocks mNCE.
Cyclopiazonic acid blocks SERCA. S(+)-Apomorphine activates the Nrf2/ARE
pathway. Melatonin directly scavenges free radicals.
studies, treatment with melatonin prolonged survival in the
SOD1G93A mice (Weishaupt et al., 2006; Zhang et al., 2013),
however, Dardiotis et al. (2013) showed contrary results in the
same mouse model, possibly because melatonin exacerbated
neurodegeneration.
In patients with ALS, high doses of melatonin were well toler-
ated (Jacob et al., 2002; Weishaupt et al., 2006) and it was reported
that circulating serum protein carbonyls, which are oxidative
stress markers, were decreased in melatonin treated ALS patients
(Weishaupt et al., 2006).
Diacetylbis(N(4)-methylthiosemicarbazonato) copper(II), that
inhibits the action of peroxynitrite on SOD1 and ensues nitra-
tion of cellular proteins, signiﬁcantly delays onset of paral-
ysis, prolongs lifespan and prevents accumulation of TDP-
43 in the spinal cord of SOD1G93A mice. Therefore, it
represents a potential neuroprotective agent targeting mul-
tiple disease pathways in ALS (Soon et al., 2011). In the
spinal cord of ALS patients, metallothioneins (Zn modula-
tors and anti-oxidant reaction inducers), were seriously reduced
(Hozumi et al., 2008). It was demonstrated that metallothionein-
III prevents the loss of motor neurons and prolongs the
life span of ALS mice (Hashimoto et al., 2011; Hozumi,
2013).
CALCIUM HOMEOSTASIS AND ROS
Ca2+ plays a role inROSproduction and, vice versa, the redox state
can modulate Ca2+ signaling. Components of ROS homeostasis
are regulated by Ca2+-dependent pathways. Ca2+ stimulates NO
synthesis, inhibits complex IV, and leads to ROS production at
the complex III (Feissner et al., 2009). Depending on the targeted
protein, the type and concentration of ROS and the duration of
exposure, interactions between Ca2+ and ROS signaling can be
stimulating or inhibiting.
Ryanodine receptors are stimulated by oxidation
Ryanodine receptors (RyR) belong to a class of intracellular Ca2+
channels and are important mediators of Ca2+ induced Ca2+
release in excitable cells such as muscles and neurons (Fabi-
ato, 1983; McPherson et al., 1991). RyR are opened by Ca2+
itself which may induce propagated Ca2+release on the ER sur-
face. Ca2+ entry through AMPA receptors caused RyR mediated
Ca2+-induced Ca2+ release from the ER in embryonic motor
neurons in co-culture with neonatal Schwan cell (Jahn et al.,
2006). In embryonic motor neurons, Ca2+-induced Ca2+ release
was shown to contribute greatly to AMPA receptor stimulation
induced Ca2+-induced Ca2+ release through RyR and Ca2+ dys-
regulation (Grosskreutz et al., 2004). RyR form tetramers in the
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sarcoplasmic reticulum (SR) and ER membranes (Xu et al., 1998;
Fill and Copello, 2002). The reversible oxidation of endogenous
SH groups opens the channel and releases Ca2+ from SR (Abram-
son and Salama, 1989; Xu et al., 1998). Since sulfhydryl oxidation
of reactive thiols is involved in the gating of the Ca2+ release chan-
nel, RyR represents an important target in oxidative cell damage
(Liu et al., 1994; Zable et al., 1997; Marengo et al., 1998). Activ-
ity of the RyR channel complex is regulated as a response to
changes in transmembrane redox potential (Feng et al., 2000).
When Ca2+ channel activators lower the redox potential of the
RyR, the thiol groups get oxidized and the channel opens. When
Ca2+ channel inhibitors increase the redox potential of the RyR,
the disulﬁdes are reduced and the channel closes (Feng et al., 2000).
ROS, such as O•−2 and H2O2, can activate the channel by direct
oxidation of redox-sensing thiols (Rowe et al., 1983; Boraso and
Williams, 1994; Zima et al., 2004). The endogenous ligand of RyR,
FKBP12, stabilizes RyR in the absence of activation and prevents
Ca2+ leakage from the ER. The concentration of FKBP12 was
decreased in ALS patients indicating the importance of equilib-
rium between FKBP12 and RyR in neurodegeneration (Kihira
et al., 2005).
IP3R are stimulated by oxidation
A second receptor that induces the release of Ca2+ from the ER
is the IP3R. Ca2+ overload in the ER discharges IP3R sponta-
neously (Missiaen et al., 1991; Rooney et al., 1991). The most
important ligands that modulate IP3R channel activity are InsP3
and Ca2+. At low concentrations Ca2+ activates the channel,
whereas at higher concentrations, Ca2+ inhibits the channel (Fos-
kett et al., 2007). IP3R can be directly activated by oxidative agents,
such as O•−2 (Suzuki and Ford, 1992) and H2O2 (Wesson and
Elliott, 1995). Thimerosal, a sulfhydryl-oxidizing agent, stimu-
lates IP3R channels isolated from rat cerebellum and incorporated
into artiﬁcial lipid bilayer (Thrower et al., 1996) and HeLa cells
(Bootman et al., 1992). Overexpression of the IP3R2 shortened
the lifespan in SOD1G93A mice, which implicates the impor-
tance of ER Ca2+ release by IP3Rs and that impaired function
of this receptor can be destructive in ALS (Staats et al., 2012a).
IP3-gated Ca2+ seems to be a key regulator of TDP-43 nucleoplas-
mic shuttling and proteostasis. Pathologic TDP-43 aggregation
disturbs Ca2+-dependent TDP-43 shuttling, indicating pharma-
cological manipulation of IP3R as a target in TDP-43 induced
neurodegeneration in vivo (Kim et al., 2012).
Phospholipase C delta 1 (PLCδ1) increases InsP3 formation
which releases calcium from ER through IP3R. The expression of
PLCδ1 is increased inALSmouse spinal cord and neurons. Genetic
ablation of PLCδ1 prevented shrinkage of motor neurons in ALS
mice, suggesting that PLCδ1 is also a candidate for new targets in
ALS research (Staats et al., 2013).
SERCA and plasma membrane Ca2+-ATPase are inhibited by
oxidation
SERCA transfers Ca2+ from the cell cytosol to the lumen of the SR
(MacLennan et al., 1997). SERCA is very sensitive to redox state
but contrary to RyR and IP3R, oxidation inhibits SERCA activity
(Kaplan et al., 2003). SERCA is reversibly regulated through NO-
dependent S-glutathiolation of speciﬁc cysteine residues (Adachi
et al., 2004), where irreversible sulfonylation reduces SERCA (Ying
et al., 2008). Thiol oxidizing agents inhibit and glutathione stim-
ulate SERCA (Scherer and Deamer, 1986). Amino acid peroxides
selectively oxidize cysteine residues of SERCA and inactivate the
pump (Dremina et al., 2007). O•−2 and H2O2/•OH have been
shown to inhibit Ca2+ uptake into the sarcoplasmic reticulum
(Rowe et al., 1983; Kukreja et al., 1988; Xu et al., 1997). H2O2/•OH
directly interfere with the ATP binding site. Since the Ca2+ uptake
into ER is coupled to the ATP hydrolysis, restriction of ATPase
activity decreases Ca2+ uptake (Xu et al., 1997). Ca2+ transport
and ATPase activity of plasmalemmal Ca2+ ATPase can be inhib-
ited by ROS due to oxidation of SH groups and peroxidation of
membrane phospholipids (Kaneko et al., 1989). In SOD1G93A
motor neurons, ER Ca2+ uptake by SERCA was shown to be
increased (Lautenschlager et al., 2013). Ca2+ handling is reshaped
during disease progression in the SOD1G93A mouse model.
Increased plasma membrane extrusion upon mitochondrial fail-
ure likely indicates a compensatorymechanism in the disease. This
study puts the focus on further investigations of mitochondrial
and plasma membrane Ca2+ transporters such as plasmalemmal
Ca2+ ATPase and plasma membrane Na+/Ca2+ exchanger (Fuchs
et al., 2013).
Therapeutic strategies targeting RyR, IP3R, and SERCA
Blocking RyR using dantrolene has provided protection of motor
neurons exposed to a brief excitotoxic insult in vitro, but did not
show a protective effect in SOD1G93A mice. This indicates that
Ca2+ release through RyRs have a modest role in SOD1 mice
(Staats et al., 2012b). Inhibiting SERCA by cyclopiazonic acid
showed protective effects against kainate induced excitotoxicity in
SOD1G93A cultured motor neurons (Lautenschlager et al., 2013).
Although there are not many studies targeting ERMCC Ca2+
channels, these could be valuable targets for further investigation.
CONCLUDING REMARKS
Riluzole is currently the only approved drug for ALS, but at best
it only slows disease progression for some months. It is cru-
cial to understand disease pathophysiology and to recognize the
major upstream events that lead to motor neuron death. Dis-
turbances of Ca2+ homeostasis and ER function are well-known
features of motor neuron degeneration in ALS. Dysregulation
in between the ERMCC is therefore characterized accumulation
of misfolded proteins, oxidative stress and motor neuron death.
Therapeutic drugs aiming to stabilize the ERMCC, reduce ER
stress and support the UPR may be effective in a wide range
of neuron diseases. However, genetic and the majority of phar-
macologic strategies to protect ER and mitochondria against
exitotoxicity have been unsuccessful. Nevertheless, these nega-
tive results, added to the many failed trials in the past, raise the
question of the suitability of our experimental models, which
are mostly murine. Perhaps we should focus on new tools such
as induced pluripotent stem cells taken from ALS patients and
derived into motor neurons. They could generate more suitible
models.
Newly discovered genes that causeALS may also offer new ther-
apeutics for ALS. These strategies are currently underway. The
SOD1G93A mice model has been extensively investigated so far,
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but there is an urgent requirement for additional models of ALS
such as TDP-43, FUS and VCP. Moreover, the drugs that failed in
clinical trials could still prove to play a valuble role as part of a
combination strategy with other molecules in the future, such as
drugs that operate in distinct or overlapping pathways. Develop-
ing of “smart drugs”, such as Arimoclomol that enhance protein
folding capacity only under conditions of cellular stress, may also
be good direction in drug development.
Finally a signiﬁcant point comprises establishing improved
pharmacokinetic proﬁles. The safety properties and most efﬁcient
dose of the drug in humans have to be adequately established prior
to phase III trials. Taken together, the key for success is in basic
and clinical researchers continuing to work together.
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